Prime Medicine, Inc. Common Stock PRME
$3.99
+11.45%
at last close
Analyst Consensus
- Consensus Rating
- Buy (5 Buy · 1 Hold · 0 Sell)
- Average Price Target
- $7.54
- Implied Upside
- +89.0%
- Price Target Range
- $4.25 – $11.00
- Analysts (12 mo)
- 6
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-09-25 | Chardan CapitalKeay Nakae |
Maintains | Buy | $7 |
| 2026-08-25 | Chardan CapitalKeay Nakae |
Maintains | Buy | $7 |
| 2026-08-19 | BMO CapitalDavid Lebowitz |
Initiates coverage on | Outperform | $9 |
| 2026-08-10 | HC Wainwright & Co.Arthur He |
Reiterates | Buy | $8 |
| 2026-06-29 | HC Wainwright & Co.Arthur He |
Upgrades | Neutral → Buy | $8 |
| 2026-03-12 | OppenheimerKostas Biliouris |
Initiates coverage on | Outperform | $11 |
| 2025-12-23 | LifeSci Capital |
Initiates coverage on | Outperform | $6 |
| 2025-11-11 | CitigroupSamantha Semenkow |
Maintains | Neutral | $5 → $4 |
| 2025-11-10 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $10 → $9 |
| 2025-08-08 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $12 → $10 |
| 2025-05-27 | CitigroupSamantha Semenkow |
Downgrades | Buy → Neutral | $10 → $2 |
| 2025-05-20 | JMP SecuritiesSilvan Tuerkcan |
Maintains | Market outperform | $10 → $6 |
| 2025-05-20 | JP MorganEric Joseph |
Downgrades | Overweight → Neutral | — |
| 2025-05-20 | HC Wainwright & Co.Arthur He |
Downgrades | Buy → Neutral | — |
| 2025-05-19 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $16 → $12 |
| 2025-03-20 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $15 → $16 |
| 2025-03-19 | HC Wainwright & Co.Arthur He |
Reiterates | Buy | $10 |
| 2025-03-04 | Citizens Capital MarketsSilvan Tuerkcan |
Reiterates | Market outperform | $10 |
| 2025-03-03 | HC Wainwright & Co.Arthur He |
Reiterates | Buy | $10 |
| 2025-03-03 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $15 |
| 2024-12-10 | JMP SecuritiesSilvan Tuerkcan |
Initiates coverage on | Market outperform | $10 |
| 2024-12-03 | GuggenheimDebjit Chattopadhyay |
Reiterates | Buy | $18 |
| 2024-11-13 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $17 → $15 |
| 2024-11-13 | HC Wainwright & Co.Arthur He |
Reiterates | Buy | $10 |
| 2024-10-25 | HC Wainwright & Co.Arthur He |
Reiterates | Buy | $10 |
| 2024-10-02 | HC Wainwright & Co.Arthur He |
Reiterates | Buy | $10 |
| 2024-08-09 | HC Wainwright & Co.Arthur He |
Reiterates | Buy | $10 |
| 2024-05-20 | HC Wainwright & Co.Arthur He |
Initiates coverage on | Buy | $10 |
| 2024-05-16 | CitigroupSamantha Semenkow |
Upgrades | Neutral → Buy | $10 |
| 2024-05-13 | JP MorganEric Joseph |
Maintains | Overweight | $16 → $15 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.99
- Market Cap
- $723.69 million
- 52-Week Range
- $2.67 – $6.94
- Average Volume
- 4.07 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.